Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Who is responsible for what?

J M Rouzioux1

  • 1Institut Mérieux, Marcy-l'Etoile, France.

Fundamental & Clinical Pharmacology
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Phase I clinical trials involve shared legal responsibilities. Pharmaceutical companies manage product and regulatory compliance, while physicians oversee volunteer selection and participant care during trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brief report: treatment of severe colchicine overdose with colchicine-specific Fab fragments.

The New England journal of medicine·1995
Same author

Safety of placental blood derivatives.

Lancet (London, England)·1994
Same author

[Epidemiology of emergency department hospitalizations for poisoning by industrial products].

Journal de toxicologie clinique et experimentale·1992
Same author

[Cyanide poisoning. Evaluation of 15 years of phone calls to the Anti-Poison Center and autopsies at the Institute of Forensic Medicine].

Journal de toxicologie clinique et experimentale·1992
Same author

Colchicine-specific Fab fragments alter colchicine disposition in rabbits.

The Journal of pharmacology and experimental therapeutics·1992
Same author

Reversal of murine colchicine toxicity by colchicine-specific Fab fragments.

Toxicology letters·1991
Same journal

The Challenges of Scientific Publishing: An Editor-In-Chief's Perspective.

Fundamental & clinical pharmacology·2026
Same journal

Glucagon-Like Peptide-1 Receptor Agonists in Cocaine Use Disorder: Clinical Observations and Underlying Mechanisms.

Fundamental & clinical pharmacology·2026
Same journal

TAAR1-Associated Trace Amines for Cutaneous Nociceptive Blockade in Rats.

Fundamental & clinical pharmacology·2026
Same journal

Synergistic Cardioprotection of Colchicine and Hyperbaric Oxygen Therapy in a Rat Model of Remote Ischemia-Reperfusion Injury.

Fundamental & clinical pharmacology·2026
Same journal

Probucol Exerts Anticancer Effects on SW480 Human Colorectal Cancer Cells via Modulation of Apoptosis- and Angiogenesis-Related Proteins.

Fundamental & clinical pharmacology·2026
Same journal

Nebivolol Protects the Thoracic and Abdominal Aorta and Their Perivascular Adipose Tissue From the Differential Detrimental Effects of Obesity.

Fundamental & clinical pharmacology·2026
See all related articles

Area of Science:

  • Clinical Research
  • Pharmaceutical Science
  • Medical Law

Background:

  • Phase I clinical trials are crucial for assessing drug safety and dosage in humans.
  • Understanding the legal framework governing these early-stage trials is essential for ethical conduct.

Purpose of the Study:

  • To delineate the distinct legal responsibilities of pharmaceutical companies and physicians in Phase I clinical trials.
  • To clarify financial liabilities and operational duties during the conduct of early-phase drug development.

Main Methods:

  • Analysis of legal precedents and regulatory guidelines pertaining to clinical trial management.
  • Review of contractual agreements between pharmaceutical sponsors and clinical investigators.

Main Results:

Related Experiment Videos

  • Pharmaceutical companies hold responsibility for the drug product, trial methodology, and regulatory adherence.
  • Physicians are accountable for the selection and ongoing care of healthy trial participants.
  • Financial liability for damages rests with the pharmaceutical company.

Conclusions:

  • Phase I trials necessitate a clear understanding of shared legal and ethical obligations.
  • Defined roles ensure participant safety and regulatory compliance in early drug development.